H. Arias-pulido, N. Joste, A. Chavez, C. Y. Muller, D. Dai et al., Absence of epidermal growth factor receptor mutations in cervical cancer, International Journal of Gynecological Cancer, vol.18, issue.4, pp.749-754, 2008.
DOI : 10.1111/j.1525-1438.2007.01111.x

T. D. Barber, B. Vogelstein, K. W. Kinzler, and V. E. Velculescu, in Colorectal Cancers and Glioblastomas, New England Journal of Medicine, vol.351, issue.27, pp.2883-2886, 2004.
DOI : 10.1056/NEJM200412303512724

J. Baselga and C. L. Arteaga, Critical Update and Emerging Trends in Epidermal Growth Factor Receptor Targeting in Cancer, Journal of Clinical Oncology, vol.23, issue.11, pp.2445-59, 2005.
DOI : 10.1200/JCO.2005.11.890

S. Berberoglu, I. Ilhan, F. Cetindag, and O. Sunter, NASOPHARYNGEAL CARCINOMA IN TURKISH CHILDREN: Review of 33 Cases, Pediatric Hematology and Oncology, vol.80, issue.5, pp.309-315, 2001.
DOI : 10.1002/1097-0142(197606)37:6<2787::AID-CNCR2820370633>3.0.CO;2-O

P. Busson, C. Keryer, T. Ooka, and M. Corbex, EBV-associated nasopharyngeal carcinomas: from epidemiology to virus-targeting strategies, Trends in Microbiology, vol.12, issue.8, pp.356-60, 2004.
DOI : 10.1016/j.tim.2004.06.005

URL : https://hal.archives-ouvertes.fr/hal-00122928

M. F. Fu, C. F. Li, Y. C. Chih, M. R. Kwen, and Y. H. Hsuan, Immunohistochemical expression of epidermal growth factor receptor and cyclooxygenase-2 in pediatric nasopharyngeal carcinomas: No significant correlations with clinicopathological variables and treatment outcomes, Int. J

T. Fukushima, F. Favereaux, H. Huang, T. Shimizu, Y. Yonekawa et al., Genetic Alterations in Primary Glioblastomas in Japan, Journal of Neuropathology and Experimental Neurology, vol.65, issue.1, pp.12-18, 2006.
DOI : 10.1097/01.jnen.0000196132.66464.96

J. Ferlay, F. Bray, P. Pisani, D. Parkin, and M. Globocan, Cancer incidence mortality and prevalence worldwide. IARC Cancer Base n:5, 2001.

N. E. Hynes, K. Horsch, M. A. Olayioye, and A. Badache, The ErbB receptor tyrosine family as signal integrators, Endocrine Related Cancer, vol.8, issue.3, pp.151-159, 2001.
DOI : 10.1677/erc.0.0080151

M. L. Janmaat, J. A. Rodriguez, M. Gallegos-ruiz, F. A. Kruyt, and G. Giaccone, Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells, International Journal of Cancer, vol.4, issue.1, pp.209-214, 2006.
DOI : 10.1002/ijc.21290

L. V. Johansen, M. Mestre, and J. Overgaard, Carcinoma of the nasopharynx; analysis of treatment results in 167 consecutively admitted patients. Head and Neck, pp.200-207, 1992.

S. Kobayashi, T. J. Boggon, T. Dayaram, P. A. Jänne, O. Kocher et al., EGFR mutation and resistance of nonsmall-cell-lung cancer to gefitinib. New Engl, J. Med, vol.352, pp.786-792, 2005.

T. Kosaka, Y. Yatabe, H. Endoh, K. Yoshida, T. Hida et al., Analysis of Epidermal Growth Factor Receptor Gene Mutation in Patients with Non-Small Cell Lung Cancer and Acquired Resistance to Gefitinib, Clinical Cancer Research, vol.12, issue.19, pp.5764-5773, 2006.
DOI : 10.1158/1078-0432.CCR-06-0714

G. E. Laramore, B. Clubb, and C. Quick, Nasopharyngeal carcinoma in Saudi Arabia: A retrospective study of 166 cases treated with curative intent, International Journal of Radiation Oncology*Biology*Physics, vol.15, issue.5
DOI : 10.1016/0360-3016(88)90193-9

G. Liu, S. Gurubhagavatula, W. Zhou, Z. Wang, B. Y. Yeap et al., Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib, The Pharmacogenomics Journal, vol.61, issue.2, pp.129-138, 2008.
DOI : 10.1158/1055-9965.EPI-04-0612

F. Lombardi, M. Gasparini, C. Gianni, M. De-marie, R. Molinari et al., Nasopharyngeal carcinoma in childhood, Medical and Pediatric Oncology, vol.20, issue.3, pp.243-50, 1982.
DOI : 10.1002/mpo.2950100304

T. J. Lynch, D. W. Bell, R. Sordella, S. Gurubhagavatula, R. A. Okimoto et al., Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non???Small-Cell Lung Cancer to Gefitinib, New England Journal of Medicine, vol.350, issue.21, pp.2129-2139, 2004.
DOI : 10.1056/NEJMoa040938

B. B. Ma, T. C. Poon, K. F. To, B. Zee, F. K. Mo et al., Prognostic significance of tumor angiogenesis, Ki 67, p53 oncoprotein, epidermal growth factor receptor and HER2 receptor protein expression in undifferentiated nasopharyngeal carcinoma?a prospective study, Head & Neck, vol.3, issue.10, pp.25864-72, 2003.
DOI : 10.1002/hed.10307

B. B. Ma, V. W. Lui, F. F. Poon, S. C. Wong, K. F. To et al., Preclinical activity of gefitinib in non-keratinizing nasopharyngeal carcinoma cell lines and biomarkers of response, Invest. New. Drugs, vol.3, pp.326-359, 2010.

A. Marchetti, C. Martella, L. Felicioni, F. Barassi, S. Salvatore et al., Mutations in Non???Small-Cell Lung Cancer: Analysis of a Large Series of Cases and Development of a Rapid and Sensitive Method for Diagnostic Screening With Potential Implications on Pharmacologic Treatment, Journal of Clinical Oncology, vol.23, issue.4, pp.857-865, 2005.
DOI : 10.1200/JCO.2005.08.043

A. Onn, A. M. Correa, M. Gilcrease, T. Isobe, E. Massarelli et al., Synchronous Overexpression of Epidermal Growth Factor Receptor and HER2-neu Protein Is a Predictor of Poor Outcome in Patients with Stage I Non-Small Cell Lung Cancer, Clinical Cancer Research, vol.10, issue.1, pp.136-143, 2004.
DOI : 10.1158/1078-0432.CCR-0373-3

W. Pao and V. A. Miller, Epidermal Growth Factor Receptor Mutations, Small-Molecule Kinase Inhibitors, and Non???Small-Cell Lung Cancer: Current Knowledge and Future Directions, Journal of Clinical Oncology, vol.23, issue.11, pp.2556-2568, 2005.
DOI : 10.1200/JCO.2005.07.799

W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi et al., EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib, Proc. Natl. Acad. Sci, pp.13306-13311, 2004.
DOI : 10.1073/pnas.0405220101

J. G. Paez, P. A. Janne, J. C. Lee, S. Tracy, H. Greulich et al., EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy, Science, vol.304, issue.5676, pp.1497-1500, 2004.
DOI : 10.1126/science.1099314

J. P. Spano, P. Busson, D. Atlan, J. Bourhis, J. P. Pignon et al., Nasopharyngeal carcinomas, European Journal of Cancer, vol.39, issue.15, pp.2121-2135, 2003.
DOI : 10.1016/S0959-8049(03)00367-8

F. L. Sung, T. C. Poon, E. P. Hui, B. B. Ma, E. Liong et al., Antitumor effect and enhancement of cytotoxic drug activity by cetuximab in nasopharyngeal carcinoma cells, pp.237-282, 2005.

S. L. Wolden, M. Zelefsky, M. A. Hunt, K. E. Rosenzweig, L. M. Chong et al., Failure of a 3D conformal boost to improve radiotherapy for nasopharyngeal carcinoma, International Journal of Radiation Oncology*Biology*Physics, vol.49, issue.5, pp.1229-1263, 2001.
DOI : 10.1016/S0360-3016(00)01588-1

W. Zhang, L. P. Stabile, P. Keohavong, M. Romkes, J. R. Grandis et al., Mutation and polymorphism in the EGFR-TK domain associated with lung cancer, J. Thorac. Oncol, vol.1, pp.635-647, 2006.